UMIN ID: UMIN000000665
Registered date:01/11/2008
EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS ON AMBULATORY BLOOD PRESSURE AND CARDIOVASCULAR FUNCTION IN HYPERTENSIVE PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Hypertension, end-stage renal disease on peritoneal dialysis |
| Date of first enrollment | 2004/09/01 |
| Target sample size | 60 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | ARB group: Start with once-daily dosing of valsartan 20-40 mg or candesartan 2-4 mg, and increase up to 80-160 mg for valsartan and 8-12 mg for candesartan, respectively, if effects of valsartan or candesartan on the clinical parameters are insufficient. Target blood pressure is less than 140/90 mmHg. Control therapy group: Treated with anti-hypertensives principally by other than ARBs or ACE inhibitors.Target blood pressure is less than 140/90 mmHg. |
Outcome(s)
| Primary Outcome | 1) body weight, residual urinary volume. 2) casual blood pressure. 3) ambulatory blood pressure profile, blood pressure variability. 4) cardiac ultrasonography (IVSd, LVDd, LVPWd, LVDs, FS, EF(modified simpson method), E/A, DcT, etc). 5) ABI/baPWV. 6) blood parameters. CBC: Hb, Ht, fibrinogen Biochemistry: TP, Alb, BUN, s-Cr, UA, Na, K, Cl, Ca, P, GOT, GPT, Alp, T-bil, T-cho, HDL, LDL, TG, beta2-microglobulin. Endocrine: cathecholamine, PRA, PAC, ANP, BNP. Serological: CRP. 7) ECG. 8) Chest Xp. 9) Weekly erythropietin dosage. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Malignancy, overt heart failure, acute myocardial infarction, collagen disease, acute renal failure, hyperkalemia, Pregnant women, or women suspected of being pregnant, history of hypersensitivity to valsartan or candesartan, severe hepatic disease |
Related Information
| Primary Sponsor | Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine |
|---|---|
| Secondary Sponsor | Fujisawa Municipal Hospital |
| Source(s) of Monetary Support | Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kazuaki UCHINO |
| Address | 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, JAPAN Japan |
| Telephone | 045-787-2634 |
| uchinok@med.yokohama-cu.ac.jp | |
| Affiliation | Yokohama City University School of Medicine Department of Medical Science |
| scientific contact | |
| Name | Kouichi TAMURA |
| Address | 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, JAPAN Japan |
| Telephone | 045-787-2635 |
| tamukou@med.yokohama-cu.ac.jp | |
| Affiliation | Yokohama City University School of Medicine Department of Cardiorenal Medicine |